Denali Therapeutics (DNLI) Accumulated Depreciation & Amortization (2017 - 2025)
Denali Therapeutics (DNLI) has disclosed Accumulated Depreciation & Amortization for 8 consecutive years, with $7.8 million as the latest value for Q4 2024.
- On a quarterly basis, Accumulated Depreciation & Amortization fell 53.37% to $7.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was $7.8 million, a 53.37% decrease, with the full-year FY2024 number at $7.8 million, down 53.37% from a year prior.
- Accumulated Depreciation & Amortization was $7.8 million for Q4 2024 at Denali Therapeutics, down from $16.7 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $16.7 million in Q4 2023 to a low of $7.8 million in Q4 2024.
- A 5-year average of $10.4 million and a median of $8.6 million in 2021 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 60.83% in 2023, then tumbled 53.37% in 2024.
- Denali Therapeutics' Accumulated Depreciation & Amortization stood at $8.5 million in 2020, then increased by 0.73% to $8.6 million in 2021, then grew by 21.03% to $10.4 million in 2022, then surged by 60.83% to $16.7 million in 2023, then crashed by 53.37% to $7.8 million in 2024.
- Per Business Quant, the three most recent readings for DNLI's Accumulated Depreciation & Amortization are $7.8 million (Q4 2024), $16.7 million (Q4 2023), and $10.4 million (Q4 2022).